Healthcare Industry News: lumbar interbody fusion
News Release - September 30, 2016
Misonix Features BoneScalpel(TM) and SonaStar(TM) Systems at Congress of Neurological Surgeons ("CNS")FARMINGDALE, N.Y., Sept. 30, 2016 -- (Healthcare Sales & Marketing Network) -- Misonix, Inc. (MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, neurosurgery, wound debridement, skull based surgery, laparoscopic surgery and other surgical applications, announced its participation at the recent Congress of Neurological Surgeons ("CNS") Annual Meeting in San Diego, CA, which took place on September 24-28, 2016.
At this year's CNS meeting, Misonix featured its BoneScalpel with ultrasonic technology and its newest product, the SonaStar Ultrasonic Surgical Aspiration System. The CNS meeting represents a premier forum for neurosurgeons and residents to share best practices and learn about the newest procedures, approaches, and technologies in all neurosurgical subspecialties. There were more than 2,000 attendees at this year's event. Activity at the Misonix exhibit was noticeably greater over this year's three-day period compared to the 2015 CNS event. Visitors to the exhibit were introduced to the BoneScalpel and SonaStar systems and provided the opportunity for hands-on demonstrations.
BoneScalpel with ultrasonic technology is being increasingly adopted by spine surgeons for the purpose of making precise and safe bone cuts during challenging spine surgeries. Common surgical applications successfully treated with BoneScalpel include deformity cases, laminectomies and transforaminal lumbar interbody fusion ("TLIF") procedures. The SonaStar Ultrasonic Aspirator is an advanced ultrasonic aspiration system which enables efficient, precise soft tissue aspiration and powerful removal of fibrous and osseous structures as required.
"The CNS Meeting is an important meeting for Misonix as we look to further expand our commercial footprint in the neurosurgery community and more broadly introduce our ultrasound technologies. I am pleased to see that a substantial number of neurosurgeons who visited with our onsite team in the exhibit have already requested system evaluations at their respective institutions," said Scott Ludecker, Senior Vice President of Global Sales and Marketing.
Commenting further, Stavros Vizirgianakis, Interim Chief Executive Officer of Misonix, offered, "We're excited to see the significant level of interest surgeons are exhibiting toward our unique platform technologies. Events like the CNS meeting are outstanding forums to allow new surgeons to gain hands-on experience with our products."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.